DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment
Aging Cell · 2026
DOI: 10.1111/acel.70430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2026. Verfasst von Jessica Kasamoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: DNA Methylation, Cellular Senescence, Senotherapeutics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Epigenetic clocks are commonly used aging biomarkers based on DNA methylation that predict long‐term morbidity and mortality risk. Increased cellular senescence with age is also posited to contribute to age‐related disease and mortality. However, prior studies have found that existing epigenetic clocks show inconsistent associations with cellular senescence and no reductions after senolytic treatment. We hypothesize this reflects that senescence‐related CpGs are a small proportion of age‐related CpGs, and that an epigenetic clock focused on a core senescence signal conserved across different cell types and different senescence inducers would be a better tool for monitoring senescence and senolytic treatment compared to traditional epigenetic clocks. In our study, we find that senescence, age and mortality risk intersect at a small subset of the DNA methylome (9363 CpGs out of 396,333 analyzed; 2.4%). Utilizing these CpGs, we generated three different epigenetic clocks trained to predict in vitro senescence, age, and mortality, respectively. Surprisingly, all three of these predictors stayed the same or even accelerated after senolytic treatment in both in vivo and in vitro data. Our findings not only call into question whether cellular senescence can be captured by DNA methylation but also challenge the assumption that aging biomarkers decrease after geroscience interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA.
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
- Institute for Hormonal Balance, Orlando, Florida, USA.
- TruDiagnostic, Lexington, Kentucky, USA.
ORCID-Profile: Jessica Kasamoto, John González, Yaroslav Markov, Raghav Sehgal
Förderung
- NIA NIH HHS
- NIH HHS
- National Institute on Aging
- National Institutes of Health
Zitieren
APA
Kasamoto, J., González, J., Markov, Y., Sehgal, R., Lee, E., Dwaraka, V. B., Smith, R., & Higgins-Chen, A. T. (2026). DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment. Aging Cell. https://doi.org/10.1111/acel.70430
Vancouver
Kasamoto J, González J, Markov Y, Sehgal R, Lee E, Dwaraka VB, et al. DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment. Aging Cell. 2026. doi:10.1111/acel.70430
BibTeX
@article{Kasamoto2026,
author = {Kasamoto, Jessica and González, John and Markov, Yaroslav and Sehgal, Raghav and Lee, Edwin and Dwaraka, Varun B and Smith, Ryan and Higgins-Chen, Albert T},
title = {DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment},
journal = {Aging Cell},
year = {2026},
doi = {10.1111/acel.70430}
}
EUVIMED